An announcement from Neurocrine ( ($NBIX) ) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive ...

Lasell University president Eric Turner is hoping that many Lasell students will find success in the real world by spending ...

Brown & Brown's fourth-quarter revenue beat analyst expectations as commissions and fees rose. The insurance company said profit fell to $210 million from $269 million a year earlier, though adjusted ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

Atomi Financial Group Inc. trimmed its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) ...

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some safety setbacks and years of generic competition, Takeda is calling it quits ...

Ascentage Pharma Group (AAPG) (AAPGV) (ASPHF), which is backed by Takeda (TAK), has priced a $126M U.S. initial public offering. Read more here.

Ballentine Partners LLC grew its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 24.3% in the 4th quarter, according to the company in its most recent filing ...

The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.

BioLife Plasma Services LP and Takeda Pharmaceuticals USA Inc. enabled third parties to intercept the personal information of ...

Some six and a half years since its debut, Servier’s U.S. arm has made good on its oncology growth ambitions while managing to stay true to its patient-centric ethos along the way. | Some six and a ...

The Senate Finance Committee will meet on Jan. 29 to discuss the confirmation of RFK Jr., whose stances on vaccines and ...